Bharadwaj Reddy’s Post

Global Demand for CAR-T Cell Therapies by Product - https://lnkd.in/gHWJUSUq In recent years, CAR-T therapies have revolutionized the treatment of certain hematological cancers, offering new hope for patients who have exhausted all other options. CAR-T therapies are a form of immunotherapy that involve modifying a patient’s own T-cells to recognize and target cancer cells more effectively. Today, seven CAR-T cell therapy products have reached the market within the U.S. and several other have received international approvals. Novartis, Kite Pharma, Bristol Myers Squibb, bluebird bio, CRISPR Therapeutics are among the key players driving the development and commercialization of CAR-T cell therapies. Read more at: https://lnkd.in/gHWJUSUq #cartcell #celltherapy #cancertreatment

Global Demand for CAR-T Cell Therapies by Product - https://lnkd.in/guW-NAfc In recent years, CAR-T therapies have revolutionized the treatment of certain hematological cancers, offering new hope for patients who have exhausted all other options. CAR-T therapies are a form of immunotherapy that involve modifying a patient’s own T-cells to recognize and target cancer cells more effectively. Today, seven CAR-T cell therapy products have reached the market within the U.S. and several other have received international approvals. Novartis, Kite Pharma, Bristol Myers Squibb, bluebird bio, CRISPR Therapeutics are among the key players driving the development and commercialization of CAR-T cell therapies. Read more at: https://lnkd.in/guW-NAfc #cartcell #celltherapy #cancertreatment

Embracing a new era in cancer treatment! CAR-T cell immunotherapy is heralding a transformative shift, offering fresh hope to patients who've exhausted traditional options. These remarkable cells have captivated the spotlight in cellular therapy advancements. While CAR-T therapies have primarily targeted hematological malignancies, recent approvals are paving the way for advancements in later-stage disease treatments (beyond the fourth line). At the American Society of Clinical Oncology (ASCO) 2024, industry leaders such as Janssen Inc., Caribou Biosciences, Autolus Therapeutics, AffyImmune Therapeutics, Bristol Myers Squibb, CARsgen Therapeutics, Oricell Therapeutics, PersonGene, AstraZeneca, AbelZeta, Imunopharm Technology, Pepromene Bio, Takeda, and many others showcased cutting-edge CAR-T treatments. Discover cutting-edge CAR-T cell therapy updates from ASCO 2024: https://lnkd.in/gwDBMuqP #asco24 #CAR-T #Immunotherapy #ASCO2024 #CancerResearch #cart #carttherapy #Innovation

US Antibody Drug Conjugates Market: Revolutionizing Cancer Treatment with Targeted Therapies Get Free PDF: https://lnkd.in/dHV3kCAJ The US Antibody Drug Conjugates (ADCs) market is witnessing a remarkable surge, valued at USD 1.3 Billion in 2023 and projected to reach USD 3.50 Billion by 2030, with a robust CAGR of 15.2%. ADCs represent a groundbreaking approach in cancer treatment, merging potent cell-killing small molecule drugs with monoclonal antibodies to precisely target tumor cells while sparing healthy tissue. #ADCs #CancerTreatment #Oncology #InnovativeTherapies #PrecisionMedicine #Healthcare #MedicalInnovation

𝙁𝘿𝘼 𝘼𝙥𝙥𝙧𝙤𝙫𝙚𝙨 𝙑𝙤𝙧𝙖𝙨𝙞𝙙𝙚𝙣𝙞𝙗: 𝘼 𝙉𝙚𝙬 𝙃𝙤𝙥𝙚 𝙛𝙤𝙧 𝙍𝙖𝙧𝙚 𝘽𝙧𝙖𝙞𝙣 𝘾𝙖𝙣𝙘𝙚𝙧 𝙋𝙖𝙩𝙞𝙚𝙣𝙩𝙨  The FDA has just approved vorasidenib, a groundbreaking treatment for a rare form of brain cancer. This new drug targets tumors with IDH1 or IDH2 mutations, offering hope to patients aged 12 and older with grade 2 astrocytoma or oligodendroglioma. 🧠 These slow-growing tumors often affect young adults, and with more than 80% of grade 2 gliomas having an IDH mutation, vorasidenib is the first systemic drug approved for these patients. 💡 Servier Pharmaceuticals estimates around 3,000 new diagnoses of IDH-mutant diffuse glioma each year in the US, with an additional 20,000 people living with the disease. Servier Pharmaceuticals is hiring for a Senior Manager, Enterprise Communications (Boston, MA Hybrid) https://lnkd.in/eAJNnEgQ #CancerTreatment #BrainCancer #FDAApproval

NEJM: Quite simply the most impressive waterfall plot I’ve ever seen in solid tumour oncology, speaking to the power of immunotherapy in biomarker selected populations. Looking forward to many more plots like this in the future as we progress our understanding of cancer biology and therapeutics. 1) Study investigated 111 patients with locally advanced dMMR colon cancer 2) 95% had a major pathological response and 68% had a complete response after only two cycles of neoadjuvant immunotherapy (nivolumab and ipilumimab) 3) With a median follow-up of more than 2 years, none of these patients have had recurrence of their disease https://lnkd.in/eKnjVwKP #medicine #research #healthcare #health #drugdevelopment #pharmaceutical #oncology #cancer #cancerresearch #biomarkers #innovation #technology

In a study funded by our division, Meisam Bagheri, Ph.D., Todd Miller, PhD, Diwakar Pattabiraman, et al. found that eribulin (an FDA-approved chemotherapeutic drug) induces chromatin remodeling to reverse epithelial to mesenchymal transition and sensitizes cancer cells to other chemotherapies in preclinical models of triple-negative #BreastCancer. https://lnkd.in/erd5cpTu

New Insights in Targeted Cancer Therapy Check out latest review in *Signal Transduction and Targeted Therapy*: "Small molecules in targeted cancer therapy: advances, challenges, and future perspectives." Since the first tyrosine kinase inhibitor in 2001, 89 small-molecule drugs have been FDA and NMPA approved. Despite progress, challenges like drug resistance remain. Review covers: - Approved drugs and clinical trial candidates - Target classifications - Current challenges and future directions Read more: https://lnkd.in/gqRV4iCX #CancerResearch #TargetedTherapy #Oncology #MedicalResearch #Pharma #Biotech

#VeryWorthwhileREADING: Tunable cell-expressor model system married with high throughput product profiling using #xCELLigence to help tackling "immune cold" modalities for low target expressing cell types. #onTargetoffTumor effect and #widerExpansion of your modality and pipeline.

Great to see our CEO, Michael Pehl, highlighted by Clarivate following the publication of its 'Companies to Watch: Antibody Drug Conjugates' report! https://lnkd.in/dbTeNsct Learn more about Adcendo and our development of first-in-class #ADCs for the treatment of #cancer with a high unmet medical need in the report here: https://lnkd.in/eWhSzAWz #biotech #oncology #lifesciences